HDP 201
Alternative Names: HDP-201Latest Information Update: 25 Oct 2024
At a glance
- Originator Heidelberg Pharma AG
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Oct 2024 Preclinical trials in Cancer in Germany (Parenteral)
- 05 Apr 2024 Pharmacodynamics and adverse events data from the preclinical studies in Colorectal cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 22 Oct 2023 Early research in Cancer in Germany (unspecified route)